ETF Holdings Breakdown of BPMC

News associated with BPMC

Exchange Traded Concepts LLC Sells 626 Shares of Blueprint Medicines Corporation (NASDAQ:BPMC)

Exchange Traded Concepts LLC reduced its position in Blueprint Medicines Corporation (NASDAQ:BPMC – Free Report) by 31.2% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 1,383 shares of the biotechnology company’s stock after selling 626 shares during the period. Exchange Traded Concepts LLC’s holdings in Blueprint Medicines […] - 2025-06-24 07:36:54

Wells Fargo & Company Downgrades Blueprint Medicines (NASDAQ:BPMC) to Hold

Blueprint Medicines (NASDAQ:BPMC – Get Free Report) was downgraded by Wells Fargo & Company from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Tuesday, MarketBeat Ratings reports. They presently have a $129.00 target price on the biotechnology company’s stock, down from their prior target price of $143.00. Wells […] - 2025-06-19 05:42:48

NBC Securities Inc. Purchases 2,646 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)

NBC Securities Inc. lifted its stake in Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 132,300.0% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,648 shares of the biotechnology company’s stock after purchasing an additional 2,646 shares during the […] - 2025-06-08 08:46:56

TD Cowen Downgrades Blueprint Medicines (NASDAQ:BPMC) to Hold

TD Cowen cut shares of Blueprint Medicines (NASDAQ:BPMC – Free Report) from a strong-buy rating to a hold rating in a research note issued to investors on Tuesday morning,Zacks.com reports. Several other brokerages have also issued reports on BPMC. Needham & Company LLC lowered shares of Blueprint Medicines from a “moderate buy” rating to a […] - 2025-06-06 05:58:54

Blueprint Medicines (NASDAQ:BPMC) Cut to Hold at Citizens Jmp

Citizens Jmp downgraded shares of Blueprint Medicines (NASDAQ:BPMC – Free Report) from a strong-buy rating to a hold rating in a report issued on Tuesday,Zacks.com reports. Several other brokerages have also issued reports on BPMC. Wedbush reissued a “neutral” rating and issued a $129.00 price target (up previously from $128.00) on shares of Blueprint Medicines […] - 2025-06-06 05:58:54

Blueprint Medicines (NASDAQ:BPMC) Stock Rating Lowered by Needham & Company LLC

Blueprint Medicines (NASDAQ:BPMC – Get Free Report) was downgraded by research analysts at Needham & Company LLC from a “moderate buy” rating to a “hold” rating in a research note issued on Monday, MarketBeat Ratings reports. They presently have a $130.00 price objective on the biotechnology company’s stock. Needham & Company LLC’s price target indicates […] - 2025-06-04 05:34:54

Scotiabank Reiterates Sector Perform Rating for Blueprint Medicines (NASDAQ:BPMC)

Scotiabank reiterated their sector perform rating on shares of Blueprint Medicines (NASDAQ:BPMC – Free Report) in a report released on Monday morning,Benzinga reports. They currently have a $135.00 price objective on the biotechnology company’s stock. Several other equities analysts have also recently issued reports on BPMC. Needham & Company LLC reiterated a “hold” rating and […] - 2025-06-03 05:52:45

Sanofi To Acquire Blueprint Medicines In $9.5 Bln Deal

(RTTNews) - Sanofi (SNYNF, SNY) announced Monday that it has agreed to acquire Blueprint Medicines Corp. (BPMC) in a transaction valued at about $9.5 billion on a fully diluted basis, including potential contingent value right payments. - 2025-06-02 05:29:00

Blueprint Medicines Co. (NASDAQ:BPMC) Stock Position Boosted by Nuveen Asset Management LLC

Nuveen Asset Management LLC increased its stake in Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 49.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 419,190 shares of the biotechnology company’s stock after acquiring an additional 138,176 shares during the […] - 2025-05-21 09:30:49

Captrust Financial Advisors Trims Stake in Blueprint Medicines Co. (NASDAQ:BPMC)

Captrust Financial Advisors reduced its position in shares of Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 53.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,331 shares of the biotechnology company’s stock after selling 9,573 shares during the period. Captrust […] - 2025-05-18 08:49:11

Ameriprise Financial Inc. Has $29.49 Million Stock Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)

Ameriprise Financial Inc. raised its holdings in shares of Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 4.2% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 338,115 shares of the biotechnology company’s stock after acquiring an additional 13,501 shares during the period. Ameriprise Financial Inc.’s holdings […] - 2025-05-14 08:41:05

Dimensional Fund Advisors LP Has $3.51 Million Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)

Dimensional Fund Advisors LP grew its stake in Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 3.1% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 40,208 shares of the biotechnology company’s stock after buying an additional 1,200 shares during the quarter. Dimensional Fund Advisors […] - 2025-05-14 07:32:47

Blueprint Medicines Co. (NASDAQ:BPMC) Receives $126.56 Average Target Price from Analysts

Blueprint Medicines Co. (NASDAQ:BPMC – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the eighteen analysts that are currently covering the firm, Marketbeat.com reports. Four analysts have rated the stock with a hold recommendation, thirteen have assigned a buy recommendation and one has given a strong buy recommendation to the company. […] - 2025-05-13 07:12:52

CANADA LIFE ASSURANCE Co Has $541,000 Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)

CANADA LIFE ASSURANCE Co lessened its stake in Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 17.8% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,220 shares of the biotechnology company’s stock after selling 1,345 shares during the quarter. CANADA LIFE ASSURANCE Co’s holdings […] - 2025-04-30 08:48:53

Needham & Company LLC Issues Pessimistic Forecast for Blueprint Medicines (NASDAQ:BPMC) Stock Price

Blueprint Medicines (NASDAQ:BPMC – Get Free Report) had its price objective lowered by analysts at Needham & Company LLC from $133.00 to $130.00 in a report released on Monday,Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. Needham & Company LLC’s target price would suggest a potential upside of 46.93% […] - 2025-04-30 05:46:52

Wells Fargo & Company MN Cuts Stock Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)

Wells Fargo & Company MN reduced its position in Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 38.9% in the fourth quarter, Holdings Channel.com reports. The fund owned 40,732 shares of the biotechnology company’s stock after selling 25,925 shares during the period. Wells Fargo & Company MN’s holdings in Blueprint Medicines were worth $3,553,000 as […] - 2025-04-23 08:06:57

Barclays PLC Buys 17,931 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)

Barclays PLC raised its stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 10.5% during the 4th quarter, HoldingsChannel reports. The firm owned 189,127 shares of the biotechnology company’s stock after purchasing an additional 17,931 shares during the quarter. Barclays PLC’s holdings in Blueprint Medicines were worth $16,494,000 as of its most […] - 2025-04-21 07:56:54

Blueprint Medicines Co. (NASDAQ:BPMC) Receives $124.95 Consensus Target Price from Analysts

Shares of Blueprint Medicines Co. (NASDAQ:BPMC – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the twenty-three analysts that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, six have issued a hold recommendation, fifteen have issued a buy recommendation and one […] - 2025-04-18 08:02:50

Blueprint Medicines Co. (NASDAQ:BPMC) Shares Sold by ExodusPoint Capital Management LP

ExodusPoint Capital Management LP decreased its stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 25.7% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,512 shares of the biotechnology company’s stock after selling 871 shares during the period. ExodusPoint Capital Management LP’s […] - 2025-04-14 07:46:56

California Public Employees Retirement System Sells 24,735 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)

California Public Employees Retirement System lowered its stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 24.0% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 78,450 shares of the biotechnology company’s stock after selling 24,735 shares during the quarter. California Public Employees Retirement System’s holdings in Blueprint Medicines were worth […] - 2025-04-08 08:18:56

Schroder Investment Management Group Sells 57,865 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)

Schroder Investment Management Group lowered its stake in Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 60.1% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 38,434 shares of the biotechnology company’s stock after selling 57,865 shares during the quarter. Schroder Investment Management […] - 2025-04-06 08:30:53

JPMorgan Chase & Co. Sells 66,018 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)

JPMorgan Chase & Co. cut its stake in Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 5.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,155,634 shares of the biotechnology company’s stock after selling 66,018 shares during the quarter. JPMorgan Chase & Co. […] - 2025-04-03 08:26:59

Corebridge Financial Inc. Trims Stock Position in Blueprint Medicines Co. (NASDAQ:BPMC)

Corebridge Financial Inc. trimmed its position in Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 6.0% during the 4th quarter, HoldingsChannel.com reports. The firm owned 31,613 shares of the biotechnology company’s stock after selling 2,006 shares during the period. Corebridge Financial Inc.’s holdings in Blueprint Medicines were worth $2,757,000 at the end of the most […] - 2025-04-01 09:36:50

Vanguard Group Inc. Grows Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)

Vanguard Group Inc. raised its position in Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 1.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,774,884 shares of the biotechnology company’s stock after buying an additional 91,450 shares during the period. […] - 2025-04-01 09:02:51

KLP Kapitalforvaltning AS Acquires Shares of 12,900 Blueprint Medicines Co. (NASDAQ:BPMC)

KLP Kapitalforvaltning AS acquired a new stake in Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 12,900 shares of the biotechnology company’s stock, valued at approximately $1,125,000. A number of other hedge funds […] - 2025-03-31 08:46:50

Brokerages Set Blueprint Medicines Co. (NASDAQ:BPMC) Target Price at $124.95

Shares of Blueprint Medicines Co. (NASDAQ:BPMC – Get Free Report) have been assigned an average rating of “Moderate Buy” from the twenty-three analysts that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, six have given a hold rating, fifteen have given a buy rating and […] - 2025-03-24 06:40:47

Zurcher Kantonalbank Zurich Cantonalbank Has $1.39 Million Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)

Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 17.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 15,936 shares of the biotechnology company’s stock after acquiring an additional 2,323 shares during […] - 2025-03-19 08:59:00

Blueprint Medicines (NASDAQ:BPMC) Now Covered by Analysts at Wolfe Research

Wolfe Research initiated coverage on shares of Blueprint Medicines (NASDAQ:BPMC – Free Report) in a report published on Tuesday morning, Marketbeat Ratings reports. The brokerage issued an outperform rating on the biotechnology company’s stock. Other equities research analysts have also recently issued research reports about the stock. StockNews.com cut shares of Blueprint Medicines from a […] - 2025-03-19 07:12:52

Raymond James Financial Inc. Makes New Investment in Blueprint Medicines Co. (NASDAQ:BPMC)

Raymond James Financial Inc. acquired a new position in shares of Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) during the fourth quarter, Holdings Channel reports. The fund acquired 241,966 shares of the biotechnology company’s stock, valued at approximately $21,104,000. A number of other hedge funds have also recently bought and sold shares of BPMC. Quarry […] - 2025-03-17 07:48:49

Bank of New York Mellon Corp Buys 7,101 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)

Bank of New York Mellon Corp increased its stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 2.4% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 303,432 shares of the biotechnology company’s stock after acquiring an additional 7,101 shares during the period. Bank of New York Mellon Corp’s holdings […] - 2025-03-10 08:54:51

BPMC institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-06-26	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	42,274	USD 5,417,413
2025-06-26	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	6,891	USD 883,082
2025-06-26	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	32,227	USD 4,129,890
2025-06-26	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	32,227	USD 4,129,890
2025-06-26	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	251	USD 32,166
2025-06-26	IE0009VWHAE6 (iShares US Equity Enhanced Active UCITS ETF USD (Acc))	4,945	USD 633,702
2025-06-19	IE000D8XC064 (iShares World Equity Enhanced Active UCITS ETF USD (Acc))	12	USD 1,537
Total =		118,827	USD 15,227,680

Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer